Drug Name. J0129 Injection, abatacept (Orencia ), 10 mg Effective 01/01/2014. J0178 Injection, aflibercept (Eylea ), 1 mg Effective 04/01/2015

Similar documents
Provider Administered Drug Program (PADP) and Physician Administered Drug VPSS List

MedStar Medicare Choice Pharmacy Services

Vivida Health Specialty Pharmacy Drugs (Injectable) Prior-Authorization Requirements Effective 1/1/19

BCBS AZ ADV PLUS * CLASSIC * PREMIER For use with members associated with the BHN Network Prior Authorization List 2015

SPECIALTY PHARMACY Master Clinical Drug List

Injections Requiring Prior Authorization

The following are J Code requirements

INJECTION, INOTUZUMAB OZOGAMICIN, 0.1 MG [BESPONSA ] [C CODES FOR FACILITY USE ONLY]

CPT Service Description Effective Date

MDwise HIP Prior Authorization and Drug List

INJECTABLE MEDICINES. Resources, Links or Additional Information. J Code Brand Names Generic names Prior Authorization or Restrictions

2016 MDwise HIP Medical Services that Require Prior Authorization

New Billing Guidelines for Home Infusion, Enteral and Parenteral Therapies Home Infusion Fee Schedule Effective July 1, 2009

Injectable Drugs Requiring Pre-Service Approval

PA Category Name Code(s) Additional Notes ABA 0364T 0365T 0366T 0367T 0373T 0374T H G0396. Applied Behavioral Analysis stage 3*

2016 MDwise HIP Medical Services that Require Prior Authorization

PA Category Name Code(s) Additional Notes ABA. Applied Behavioral Analysis stage 3*

PRESCRIPTION DRUGS REQUIRING PRIOR AUTHORIZATION

MDwise Hoosier Care Connect Medical Services that Require Prior Authorization

Pharmacy and Medical Guideline Updates

HCPCS Code/ generic (Brand) Name J7506. J8520 capecitabine (Xeloda) 1. J8521 capecitabine. J8530 cyclophosphamide. (Cytoxan) 1

STAT Bulletin. Drug Therapy Guideline Updates. To: All Primary Care Physicians and Specialists Contracts Affected: All Lines of Business

2018 MDwise Excel Network Hoosier Healthwise Medical Services that Require Prior Authorization

2018 MDwise Excel Network Hoosier Healthwise Medical Services that Require Prior Authorization

2017 MDwise HIP Medical Services that Require Prior Authorization

Medications currently available to treat Multiple Myeloma include: Current Code Price (AWP) Effective Date. Code Price (AWP)

PRESCRIPTION DRUGS REQUIRING PRIOR AUTHORIZATION

Pre-authorization Form

List of Designated High-Cost Drugs

Essential Health Benefits Standard Specialty PA and QL List July 2016

LIST OF DRUGS THAT MAY BE COVERED UNDER YOUR MEDICAL BENEFIT

Pharmacy Services Request Types

Criteria for Medical Benefit Drugs Requiring Clinical Review

2018 MDwise HIP Medical Services that Require Prior Authorization

Leukemia. Treatment of. compendia. Associated ICD-9-CM Codes: Drug & Administration. managedcareoncology.com

Criteria for Medical Benefit Drugs Requiring Clinical Review

STAT Bulletin. Drug Therapy Guideline Updates. To: All Primary Care Physicians and Specialists Contracts Affected: All Lines of Business

2018 MDwise HIP Medical Services that Require Prior Authorization

2018 MDwise HIP Medical Services that Require Prior Authorization

Drug Use Evaluation: Physician Administered Drugs (PADs)

Drug Infusion Site of Care Policy

Original Policy Date

J1556 INJECTION, IMMUNE GLOBULIN (BIVIGAM) 500 MG $ J1559 INJECTION, IMMUNE GLOBULIN (HIZENTRA) 100 MG $14.364

Clinical UM Guidelines for Indiana, Kentucky, Missouri, Ohio and Wisconsin

Part B payment for drugs in Medicare 0

BCN Advantage SM requirements for drugs covered under the medical benefit

State: Virginia. Clinical Guidelines Applicable for Virginia

DME MAC Jurisdiction B Drug Fees, Pharmacy Dispensing Fees and Pharmacy Supply Fees Effective 01/01/2019 through 03/31/2019

DME MAC Jurisdiction C Drug Fees, Pharmacy Dispensing Fees and Pharmacy Supply Fees Effective 01/01/2018 through 03/31/2018

Highmark List of Procedure Codes Requiring NDC Effective 12/01/2017

Part B payment for drugs in Medicare: Phase 1 of CMS s proposed pilot and its impact on oncology care

Part B payment for drugs in Medicare 0

Special Notes Implementation Date by CO. State CG number CG title CG Category Original Current Version

FIDELIS CARE NEW YORK DEPARTMENT OF PHARMACY SERVICES J Code Prior Authorizations & Required Clinical Information 2011 (Updated 3/14/11)

Medical Policies and Clinical Utilization Management Guidelines

Committee Approval Date: December 12, 2014 Next Review Date: July 2015

Formulary Chemotherapy Agents: (Current as of 6/2018) Therapeutic Class

Clinical Utilization Management Guidelines update

Brand Generic J-Code 1 Billable. Exclusion Criteria. Information and Criteria. Unit

Billing for Infusion Services in an Outpatient Neurology Clinic. Christine Mann, MBA Director of Infusion Services Dent Neurologic Institute

METABOLIC, IMMUNE DISORDERS OR INHERITED RARE DISEASE ALPHA-1 PROTEINASE INHIBITORS ARANESP BLOOD CELL DEFICIENCY ARANESP ARCALYST

Medical Prior Authorization List Rosen Employee Plans For prescription drug requirements, contact EHIM toll-free at

March 2017 Pharmacy & Therapeutics Committee Decisions

after reconstitution No Yes Refrigerate; do Not freeze. Discard unused portions; do Not save for further Immune Deficiencies & Related

Clinical Utilization Management Guidelines

Prior treatment with non-biologic Disease- Modifying Antirheumatic. Not to be used in combination with another biologic DMARD

Provider Newsletter. Table of Contents. Reimbursement Policy: Improve member medication regimen. Page 2

Clinical Utilization Management Guidelines

Clinical Utilization Management Guidelines

Clinical Utilization Management Guidelines

Clinical Utilization Management Guidelines

Clinical Utilization Management Guidelines

Clinical Utilization Management Guidelines

Premera Blue Cross Medicare Advantage Plans Medical Policy Updates

Medical Policies and Clinical Utilization Management Outpatient Guidelines

Clinical Utilization Management Guidelines

Clinical Utilization Management Guidelines

To help doctors give their patients the best possible care, the American

MEDICAL POLICY No R10 INFUSION SERVICES & EQUIPMENT

Anthem Blue Cross and Blue Shield Commercial Professional Reimbursement Policy

Actemra. Products Affected ACTEMRA INTRAVENOUS. Covered Uses

Medical Policies and Clinical Utilization Management Guidelines

Medical Policies and Clinical Utilization Management Guidelines

Percent Brand Name Generic Name Strength How Supplied NDC from AWP/SWP Adcetris. Amprya dalfampridine 10 mg 60 count bottle

Prescription Drug Benefit Rider V

Ovarian Cancer. compendia TREATMENT OF

ICON Formulary - October 2018 Legend - ICON Protocols Essential (previously Standard), Core, Enhanced Core, Enhanced Enhanced

Medical Policies and Clinical Utilization Management Guidelines

Modular Program Report

Medical Policies and Clinical Utilization Management Guidelines

Pulmonary Hypertension Weight Loss Skin Conditions. Skin Conditions Multiple Sclerosis Endocrine Disorder. Endocrine Disorder.

Haematology, Oncology and Palliative Care Directorate.

Prescription Drug Benefit Rider

J-Code Trade Name Drug Name Required Medical Information

Health Choice Generations HMO Medicare Advantage Special Needs Plan PRIOR AUTHORIZATION GUIDELINES

September 2018 Pharmacy & Therapeutics Committee Decisions

Utilization Management

Transcription:

J0129 Injection, abatacept (Orencia ), 10 J0178 Injection, aflibercept (Eylea ), 1 J0256 J0257 J0585 J0586 J0587 J0588 J0597 J0641 J0717 J0800 Injection, alpha 1-proteinase inhibitor, human (Aralast NP, Prolastin, Zemairra ), 10, not otherwise specified Injection, alpha 1 proteinase inhibitor (human)(glassia ), 10 Injection, onabotulinumtoxina (Botox, Botox Cosmetic), 1 unit Injection, abobotulinumtoxina (Dysport ), 5 units Injection, rimabotulinumtoxinb (Myobloc ),100 units Injection, incobotulinumtoxina (Xeomin ), 1 unit Injection, C-1 esterase inhibitor (human)(berinert ), 10 units Injection, levoleucovorin calcium (Fusilev ), 0.5 Injection, certolizumab pegol (Cimzia ), 1 (code may be used for Medicare when drug administered under the direct supervision of a physician, not for use when drug is self-administered) Injection, corticotropin (H.P. Acthar Gel), up to 40 units J0881 Darbepoetin Alfa (Aranesp ), 1 microgram (non-esrd use)

J0885 J0897 Epoetin Alfa (Epogen, Procrit ), (for non-esrd use), 1000 units Injection, denosumab (Prolia, Xgeva ), 1 J1290 Injection, ecallantide (Kalbitor ), 1 J1300 Injection, eculizumab (Soliris ), 10 J1442 J1447 J1459 J1556 Injection, filgrastim (G-CSF) (Neupogen ), 1 microgram Injection, tbo-filgrastim (Granix), 1 mcg Injection, immune globulin (Privigen), intravenous, nonlyophilized (e.g., liquid), 500 Injection, immune globulin (Bivigam), 500 Effective 01/01/ J1557 J1561 J1562 J1566 Injection, immune globulin, (Gammaplex) intravenous, nonlyophilized (e.g., liquid), 500 Injection, immune globulin, (Gamunex- C,Gammaked), nonlyophilized (e.g., liquid), 500 Injection, immune globulin (vivaglobin), 100 Injection, immune globulin, intravenous, lyophilized (e.g., powder) (Carimune NF, Panglobulin NF and Gammagard S/D), not otherwise specified, 500 Eff. 01/16/2012 Termed 12/31/2014

J1568 J1569 J1572 J1599 Injection, immune globulin, (Octagam), intravenous, nonlyophilized (e.g., liquid), 500 Injection, immune globulin, (Gammagard Liquid), intravenous Injection, immune globulin, (Flebogamma/Flebogamma DIF), intravenous, nonlyophilized (e.g., liquid), 500 Injection, immune globulin, intravenous. nonlyophilized (e.g., liquid), not otherwise specified, 500 J1745 Injection, infliximab (Remicade ), 10 J1786 Injection, imiglucerase (Cerezyme ), 10 units J1950 Injection, leuprolide acetate (for depot suspension)(lupron Depot, Lupron Depot-PED ), per 3.75 J2323 Injection, natalizumab (Tysabri ), 1 J2353 Injection, octreotide (SandoSTATIN LAR), depot form for intramuscular injection, 1 J2357 Injection, omalizumab (Xolair ), 5 J2469 Palonosetron Hydrochloride (Aloxi ), 25 mcg J2503 Injection, pegaptanib sodium (Macugen), 0.3 J2505 Injection, pegfilgrastim (Neulasta ), 6

J2778 Injection, ranibizumab (Lucentis ), 0.1 J2796 Injection, romiplostim (Nplate ), 10 micrograms J3262 Injection, tocilizumab (Actemra ), 1 J3315 Injection, triptorelin pamoate (Trelstar ), 3.75 J3357 Injection, ustekinumab (Stelara ), 1 J3385 J3380 J3489 J3590 J7321 J7323 J7324 J7325 Injection, velaglucerase alfa (VIPRIV ), 100 units Injection, vedolizumab (Entyvio), 1 Injection, zoledronic acid (Reclast, Zometa ), 1 NDC: 64764-0300-20 Injection, vedolizumab (Entyvio ), 1 Hyaluronan or derivative (Hyalgan or Supartz ) for intra-articular injection, per dose Hyaluronan or derivative (Euflexxa ) for intra-articular injection, per dose Hyaluronan or derivative (Orthovisc ) for intra-articular injection, per dose Hyaluronan or derivative (Synvisc or Synvisc-One ) for intra-articular injection, 1 Effective 01/01/ Code termed 12/31/15- refer to Classified code J3380

J7326 J7327 J7328 Hyaluronan or derivative (Gel-One ) for intra-articular injection, per dose Hyaluronan or derivative (Monovisc), for intra-articular injection, per dose Hyaluronan or derivative (Gel-Syn), for intra-articular injection, 0.1 Effective 01/01/2015 Effective 01/01/ J9025 Injection, azacitidine (Vidaza ), 1 J9033 Injection, bendamustine HCl (Treanda ), 1 J9035 Injection, bevacizumab (Avastin ), 10 J9041 Injection, bortezomib (Velcade ), 0.1 J9043 Injection, cabazitaxel (Jevtana ), 1 J9055 Injection, cetuximab (Erbitux), 10 J9155 Injection, degarelix (Firmagon ), 1 Effective 04/1/2013 Termed 12/31/2014 J9171 J9179 J9202 J9217 Injection, docetaxel (Taxotere, Docefrez ), 1 Injection, eribulin mesylate (Halaven), 0.1 Goserelin acetate implant (Zoladex ), per 3.6 Leuprolide acetate (for depot suspension)(eligard, Lupron Depot ), 7.5 J9225 Histrelin implant (Vantas ), 50 J9226 Histrelin implant (Supprelin LA), 50

J9228 Injection, ipilimumab (Yervoy ), 1 J9263 Injection, oxaliplatin (Eloxatin ), 0.5 J9264 Injection, paclitaxel protein-bound particles (Abraxane ), 1 J9303 Injection, panitumumab (Vectibix), 10 J9305 Injection, pemetrexed (Alimta ), 10 J9310 Injection, rituximab (Rituxan ), 100 J9354 Injection, ado-trastuzumab emtansine (Kadcyla ), 1 J9355 Injection, trastuzumab (Herceptin ), 10 Q2043 Q2049 Q2050 Q5101 Q9980 Sipuleucel-T (Provenge ), minimum of 50 million autologous CD54+ cells activated with PAP-GM-CSF, including leukapheresis and all other preparatory procedures, per infusion Injection, Doxorubicin Hydrochloride, Liposomal, Imported Lipodox (Lipodox ), 10 Injection, Doxorubicin Hydrochloride, Liposomal, Not Otherwise Specified, 10 Injection, filgrastim, biosimilar, 1mcg Hyaluronan or derivative (Genvisc 850), for intra-articular injection, 1 Effective 07/01/2015 Effective 01/01/